Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DMG Deutsche Malaria
Hamburg, Hamburg, Germanydmg-deutschemalaria.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DMG Deutsche Malaria (formerly Jomaa Pharma) has developed a novel oral antimalarial therapy based on the antibiotic fosmidomycin combined with piperaquine. Clinical studies in Gabon demonstrated a 100% cure rate with excellent safety and tolerance in both children and adults. The company is also developing a triple combination therapy for severe malaria using fosmidomycin, clindamycin, and artesunate; this is entering early clinical trials[1].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeAntibiotic
- Industry
- Biotech
02
Partnerships
Medicines for Malaria Venture (MMV)European and Developing Countries Clinical Trials Partnership (EDCTP)
Beyond the preview
Go deeper on DMG Deutsche Malaria.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMG Deutsche Malaria.